Full TitleA Phase 1/2A, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TRKA, TRKB, TRKC, ROS1, or ALK Molecular Alterations Back to top
RXDX-101 is an investigational drug that inhibits altered versions of the proteins TRKA, TRKB, TRKC, ROS1, or ALK. When these proteins are altered, they can cause normal cells to become abnormal and form tumors. Laboratory studies have shown that RXDX-101 can shrink tumors with molecular changes in these proteins.
The purpose of this study is to find the highest dose of RXDX-101 that can be given safely in patients with locally advanced or metastatic cancers containing alterations in the TRKA, TRKB, TRKC, ROS1, or ALK proteins. RXDX-101 is taken orally (by mouth).Back to top
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a locally advanced or metastatic solid tumor that contains molecular changes in the TRKA, TRKB, TRKC, ROS1, or ALK proteins.
- At least 2 to 4 weeks must pass between the completion of prior therapies and entry into the study.
- Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.